Drug · CHEMBL1789844
IPILIMUMAB
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. IPILIMUMAB. Drugs and targets, record CHEMBL1789844. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL1789844
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Open Targets' highest stage
- Approval, for 7 of its 193 diseases, from ATC, DailyMed, EMA Human Drugs, PMDA and TTD
- Open Targets
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| CTLA4 | Cytotoxic T-lymphocyte protein 4 | Cytotoxic T-lymphocyte protein 4 inhibitor | INHIBITOR | https://conductscience.org/library/genes/1493 |
Source ChEMBL
Diseases193
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| melanoma | Approval | DailyMed, EMA Human Drugs, PMDA and TTD | 246 | 242 | https://conductscience.org/library/drugs?q=MONDO_0005105 |
| non-small cell lung carcinoma | Approval | EMA Human Drugs | 93 | 92 | https://conductscience.org/library/drugs?q=MONDO_0005233 |
| renal cell carcinoma | Approval | EMA Human Drugs | 55 | 53 | https://conductscience.org/library/drugs?q=MONDO_0005086 |
| prostate cancer | Phase 3 | ClinicalTrials.gov | 37 | 37 | https://conductscience.org/library/drugs?q=MONDO_0008315 |
| hepatocellular carcinoma | Phase 3 | ClinicalTrials.gov | 25 | 25 | https://conductscience.org/library/drugs?q=MONDO_0007256 |
| colorectal cancer | Phase 3 | ClinicalTrials.gov | 19 | 19 | https://conductscience.org/library/drugs?q=MONDO_0005575 |
| head and neck squamous cell carcinoma | Phase 3 | ClinicalTrials.gov | 19 | 19 | https://conductscience.org/library/drugs?q=MONDO_0010150 |
| breast cancer | Phase 2 | ClinicalTrials.gov | 17 | 17 | https://conductscience.org/library/drugs?q=MONDO_0007254 |
| cancer | Phase 2/3 | ClinicalTrials.gov | 17 | 17 | https://conductscience.org/library/drugs?q=MONDO_0004992 |
| small cell lung carcinoma | Phase 3 | ClinicalTrials.gov and TTD | 18 | 16 | https://conductscience.org/library/drugs?q=MONDO_0008433 |
1 to 10 of 193Source Open Targets
See all 193 diseasesTrials809
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 3 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT02477826 | An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) | Phase 3 | 2,747 | 2025-10-30 | ipilimumab | Its name | ClinicalTrials.gov |
| NCT02872116 | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer | Phase 3 | 2,031 | 2022-06-28 | ipilimumab | Its name | ClinicalTrials.gov |
| NCT03068455 | An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma | Phase 3 | 1,844 | 2021-07-22 | ipilimumab | Its name | ClinicalTrials.gov |
| NCT00094653 | MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma | Phase 3 | 1,783 | 2011-06-23 | ipilimumab | Its name | ClinicalTrials.gov |
| NCT01274338 | Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery | Phase 3 | 1,673 | 2021-05-27 | ipilimumab | Its name | ClinicalTrials.gov |
| NCT03138512 | A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney | Phase 3 | 1,641 | 2024-12-18 | ipilimumab | Its name | ClinicalTrials.gov |
| NCT01450761 | Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone | Phase 3 | 1,351 | 2016-07-18 | ipilimumab | Its name | ClinicalTrials.gov |
| NCT03036098 | Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer | Phase 3 | 1,314 | 2025-09-18 | ipilimumab | Its name | ClinicalTrials.gov |
| NCT02506153 | Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery | Phase 3 | 1,301 | 2024-08-27 | ipilimumab | Its name | ClinicalTrials.gov |
| NCT01285609 | Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin | Phase 3 | 1,289 | 2016-06-23 | ipilimumab | Its name | ClinicalTrials.gov |
1 to 10 of 809
See all 809 trialsComparisons in its trials208
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Arm A: Nivo + Ipi vs Arm B: Nivo: deaths from any cause | 122 of 916 | 121 of 917 | 1,833 | NCT03068455 | Trial comparisons |
| Arm A: Nivo + Ipi vs Arm B: Nivo: serious adverse events | 374 of 916 | 242 of 917 | 1,833 | NCT03068455 | Trial comparisons |
| FDA Approved Regimen vs MK-3475 (Pembrolizumab): deaths from any cause | 130 of 654 | 131 of 647 | 1,301 | NCT02506153 | Trial comparisons |
| FDA Approved Regimen vs MK-3475 (Pembrolizumab): serious adverse events | 23 of 565 | 125 of 639 | 1,204 | NCT02506153 | Trial comparisons |
| 10 MG/KG IPILIMUMAB + PLATINUM/ETOPOSIDE vs PLACEBO + PLATINUM/ETOPOSIDE: serious adverse events | 316 of 562 | 278 of 561 | 1,123 | NCT01450761 | Trial comparisons |
| Nivolumab + Ipilimumab vs Sunitinib: deaths from any cause | 159 of 547 | 202 of 535 | 1,082 | NCT02231749 | Trial comparisons |
| Nivolumab + Ipilimumab vs Sunitinib: serious adverse events | 305 of 547 | 213 of 535 | 1,082 | NCT02231749 | Trial comparisons |
| Ipilimumab 10mg/kg vs Placebo: Number of Participants With Recurrence or Death as Per Independent Review Committee (IRC) in the Intent to Treat (ITT) Population | 234 of 475 | 294 of 476 | 951 | NCT00636168 | Trial comparisons |
| Ipilimumab 10mg/kg vs Placebo: Number of Participants With Distant Metastasis-Free Survival (DMFS) Per Independent Review Committee (IRC) in the Intent to Treat (ITT) Population | 227 of 475 | 279 of 476 | 951 | NCT00636168 | Trial comparisons |
| 10 MG/KG Ipilimumab + Paclitaxel/ Carbop vs Placebo + Paclitaxel/ Carboplatin: deaths from any cause | 359 of 475 | 371 of 473 | 948 | NCT01285609 | Trial comparisons |
1 to 10 of 208
See all 208 comparisons in its trialsPapers from its trials635
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials3
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Verbal Learning | 2 | 0 | ConductCognition |
| Trail Making Test A | 1 | 0 | ConductCognition |
| Verbal Fluency | 1 | 0 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL1789844
GET https://conductscience.org/api/drugs/v1/CHEMBL1789844/diseases?page=2